Additional Information

Description

Opdualag 240 mg-80 mg/20 mL VL Ea is a combination immunotherapy product used in the treatment of certain cancers. It contains two active ingredients: nivolumab, an anti-PD-1 monoclonal antibody, and relatlimab, an anti-LAG-3 monoclonal antibody. Nivolumab works by blocking the PD-1 receptor, which normally inhibits T-cell activity, while relatlimab targets the LAG-3 receptor, further stimulating immune function.

This medication is administered as an intravenous infusion and is typically used for patients with melanoma or other malignancies that have not responded to conventional treatments. By inhibiting both the PD-1 and LAG-3 pathways, Opdualag aims to activate T-cells more effectively, allowing the immune system to recognize and destroy cancer cells.

Opdualag is available in a 20 mL vial, with each dose containing 240 mg of nivolumab and 80 mg of relatlimab. Dosing schedules vary depending on the specific type of cancer being treated and patient factors. The infusion must be administered under the supervision of a qualified healthcare provider in a clinical setting.